Abstract
First generation HIV vaccines may have limited ability to prevent infection. Instead, they may delay the onset of AIDS or reduce the infectiousness of vaccinated individuals who become infected. To assess the population level effects of such a vaccine, we formulate a deterministic model for the spread of HIV in a homosexual population in which the use of highly active antiretroviral therapy (HAART) to treat HIV infection is incorporated. The basic reproduction number R 0 is obtained under this model. We then expand the model to include the potential effects of a prophylactic HIV vaccine. The reproduction number R f is derived for a population in which a fraction f of susceptible individuals is vaccinated and continues to benefit from vaccination. We define f * as the minimum vaccination fraction for which R f ≤ 1 and describe situations in which it equals the critical vaccination fraction necessary to eliminate disease. When R 0 is large or an HIV vaccine is only partially effective, the critical vaccination fraction may exceed one. HIV vaccination, however, may still reduce the prevalence of disease if the reduction in infectiousness is at least as great as the reduction in the rate of disease progression. In particular, a vaccine that reduces infectiousness during acute infection may have an important public health impact especially if coupled with counseling to reduce risky behavior.
Article PDF
Similar content being viewed by others
References
Abu-Raddad, L., Boily, M., Self, S., Longini, I. Jr., 2007. Analytic insights into the population level impact of imperfect prophylactic HIV vaccines. J. Acquir. Immune Defic. Syndr. 45(4), 454–67.
Anderson, R., Hanson, M., 2005. Potential public health impact of imperfect HIV type 1 vaccines. J. Infect. Dis. 191(S1), S85–S96.
Anderson, R., Swinton, J., Garnett, G., 1995. Potential impact of low efficacy HIV-1 vaccines in populations with high rates of infection. Proc. R. Soc. Lond. Ser. B - Biol. Sci. 261(1361), 147–51.
Arino, J., Cooke, K., van den Driessche, P., Velasco-Hernandez, J., 2004. An epidemiology model that includes a leaky vaccine with a general waning function. Discrete Contin. Dyn. Syst. Ser. B 4(2), 479–95.
Babiker, A., Darby, S., De Angelis, D., Ewart, D., Porter, K., 2000. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly active antiretroviral therapy: a collaborative reanalysis. Lancet 355, 1131–137.
Baggaley, R., Garnett, G., Ferguson, N., 2006. Modelling the impact of antiretroviral use in resource-poor settings. PLoS Med. 3(4), e124.
Bartlett, J., Lane, H., Anderson, J., Baker, A., Bozzette, S., Carpenter, C., Delaney, M., El-Sadr, L., Fletcher, C. et al., 2006. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. DHHS-Office of AIDS Research Advisory Council.
Blower, S., Bodine, E., Grovit-Ferbas, K., 2005. Predicting the potential public health impact of disease-modifying HIV vaccines in South Africa: the problem of subtypes. Curr. Drug Targets–Infect. Disord. 5, 179–92.
Blythe, S., Castillo-Chavez, C., 1989. Like-with-like preference and sexual mixing models. Math. Biosci. 96(2), 221–38.
Burr, C., 1998. Of AIDS and altruism. US News World Rep. 124(13), 60–1.
Cohen, J., 2007. AIDS research: promising AIDS vaccine’s failure leaves field reeling. Science 318(5847), 28–9.
Davenport, M., Ribeiro, R., Chao, D., Perelson, A., 2004. Predicting the impact of a nonsterilizing vaccine against human immunodeficiency virus. J. Virol. 78(20), 11,340–1,351.
Deeks, S., 2003. Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet 362(9400), 2002–011.
Del Valle, S., Morales Evangelista, A., Cristina Velasco, M., Kribs-Zaleta, C., Hsu Schmitz, S., 2004. Effects of education, vaccination and treatment on HIV transmission in homosexuals with genetic heterogeneity. Math. Biosci. 187(2), 111–33.
Diekmann, O., Hesterbeck, J., Metz, J., 1990. On the definition and the computation of the basic reproductive rate ratio r 0 in heterogeneous populations. J. Math. Biol. 28, 365–82.
Dietz, K., 1993. The estimation of the basic reproduction number for infectious diseases. Stat. Methods Med. Res. 2(1), 23–4.
Dushoff, J., 1996. Incorporating immunological ideas in epidemiological models. J. Theor. Biol. 180(3), 181–87.
Elbasha, E., Gumel, A., 2006. Theoretical assessment of public health impact of imperfect prophylactic HIV-1 vaccines with therapeutic benefits. Bull. Math. Biol. 68(3), 577–14.
Gilbert, P., DeGruttola, V., Hudgens, M., Self, S., Hammer, S., Corey, L., 2003. What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials. J. Infect. Dis. 188(2), 179–93.
Goebel, F., 2005. Immune reconstitution inflammatory syndrome (IRIS) another new disease entity following treatment initiation of HIV infection. Infection 33(1), 43–5.
Gray, R., Wawer, M., Brookmeyer, R., Sewankambo, N., Serwadda, D., Wabwire-Mangen, F., Lutalo, T., Li, X., vanCott, T., Quinn, T., 2001. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 357(9263), 1149–153.
Gumel, A., McCluskey, C., van den Driessche, P., 2006. Mathematical study of a staged-progression HIV model with imperfect vaccine. Bull. Math. Biol. 68(8), 2105–128.
Hoyert, D., Kung, H., Smith, B., 2005. Deaths: preliminary data for 2003. Nat. Vital Stat. Rep. 53(15), 1–8.
Hsu Schmitz, S., 2000. Effects of treatment or/and vaccination on HIV transmission in homosexuals with genetic heterogeneity. Math. Biosci. 167(1), 1–8.
Huang, W., Cooke, K., Castillo-Chavez, C., 1992. Stability and bifurcation for a multiple-group model for the dynamics of HIV/AIDS transmission. SIAM J. Appl. Math. 52, 835–54.
Hyman, J., Li, J., Stanley, E., 1999. The differential infectivity and staged progression models for the transmission of HIV. Math. Biosci. 155(2), 77–09.
IAVI, 2007. International AIDS Vaccine Initiative vaccine database. http://www.iavi.org.
Jacobson, L., Phair, J., Yamashita, T., 2004. Update on the virologic and immunologic response to highly active antiretroviral therapy. Curr. Infect. Dis. Rep. 6(4), 325–32.
Jacquez, J., Simon, C., Koopman, J., Sattenspiel, L., Perry, T., 1988. Modeling and analyzing HIV transmission: the effect of contact patterns. Math. Biosci. 92(2), 119–99.
Katz, M., Schwarcz, S., Kellogg, T., Klausner, J., Dilley, J., Gibson, S., McFarland, W., 2002. Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco. Am. J. Public Heath 92, 388–94.
Kgosimore, M., Lungu, E., 2004. The effects of vaccination and treatment on the spread of HIV/AIDS. J. Biol. Syst. 12(4), 399–17.
King, J. Jr., Justice, A., Roberts, M., Chang, C., Fusco, J., 2003. Long-term HIV/AIDS survival estimation in the highly active antiretroviral therapy era. Med. Decis. Mak. 23(1), 9–0.
Kretzschmar, M., Dietz, K., 1998. The effect of pair formation and variable infectivity on the spread of an infection without recovery. Math. Biosci. 148(1), 83–13.
Kribs-Zaleta, C., Velasco-Hernández, J., 2000. A simple vaccination model with multiple endemic states. Math. Biosci. 164(2), 183–01.
Lin, X., Hethcote, H., Van den Driessche, P., 1993. An epidemiological model for HIV/AIDS with proportional recruitment. Math. Biosci. 118(2), 181–5.
Louie, J., Hsu, L., Osmond, D., Katz, M., Schwarcz, S., 2002. Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco, 1994–998. J. Infect. Dis. 186(7), 1023–027.
Lyles, R., Munoz, A., Yamashita, T., Bazmi, H., Detels, R., Rinaldo, C., Margolick, J., Phair, J., Mellors, J., 2000. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. J. Infect. Dis. 181(3), 872–80.
Macey, R., Oster, G., 2000. Berkeley madonna. Version 801.
Massad, E., Coutinho, F., Burattini, M., Lopez, L., Struchiner, C., 2001. Modeling the impact of imperfect HIV vaccines on the incidence of the infection. Math. Comput. Model. 34(3–4), 345–51.
McCluskey, C., 2003. A model of HIV/AIDS with staged progression and amelioration. Math. Biosci. 181(1), 1–6.
Montaner, J., Hogg, R., Wood, E., Kerr, T., Tyndall, M., Levy, A., Harrigan, P., 2006. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 368(9534), 531–36.
Morris, M., Kretzschmar, M., 1997. Concurrent partnerships and the spread of HIV. AIDS 11(5), 641–48.
Paltiel, A., Weinstein, M., Kimmel, A., Seage, G. III, Losina, E., Zhang, H., Freedberg, K., Walensky, R., 2005. Expanded screening for HIV in the United States—an analysis of cost-effectiveness. N. Engl. J. Med. 352(6), 586–95.
Pilcher, C., Tien, H., Eron, J. Jr., Vernazza, P., Leu, S., Stewart, P., Goh, L., Cohen, M. , 2004. Brief but efficient: acute HIV infection and the sexual transmission of HIV. J. Infect. Dis. 189(10), 1785–792.
Pitisuttithum, P., Gilbert, P., Gurwith, M., Heyward, W., Martin, M., van Griensven, F., Hu, D., Tappero, J., Choopanya, K. , 2006. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194(12), 1661–671.
Porco, T., Martin, J., Page-Shafer, K., Cheng, A., Charlebois, E., Grant, R., Osmond, D., 2004. Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS 18(1), 81–8.
Quinn, T., Wawer, M., Sewankambo, N., Serwadda, D., Li, C., Wabwire-Mangen, F., Meehan, M., Lutalo, T., Gray, R., 2000. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai project study group. N. Engl. J. Med. 342(13), 921–29.
Rerks-Ngarm, S., Brown, A., Khamboonruang, C., Thongcharoen, P., Kunasol, P., 2006. HIV/AIDS preventive vaccine’prime-boost’phase III trial: foundations and initial lessons learned from Thailand. AIDS 20(11), 1471–479.
rgp120 HIV Vaccine Study Group, 2005. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191, 654–65.
Safan, M., Heesterbeek, H., Dietz, K., 2006. The minimum effort required to eradicate infections in models with backward bifurcation. J. Math. Biol. 53(4), 703–18.
Sanders, G., Bayoumi, A., Sundaram, V., Bilir, S., Neukermans, C., Rydzak, C., Douglass, L., Lazzeroni, L., Holodniy, M., Owens, D., 2005. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N. Engl. J. Med. 352(6), 570–85.
Sifakis, F., Flynn, C., Metsch, L., LaLota, M., Murrill, C., Koblin, B., Bingham, T., McFarland, W., Raymond, H., Behel, S. , 2005. HIV prevalence, unrecognized infection, and HIV testing among men who have sex with men-five US cities, June 2004–April 2005. Morb. Mortal. Wkly. Rep. 54(24), 597–01.
Smith, P., Rodrigues, L., Fine, P., 1984. Assessment of the protective efficacy of vaccines against common diseases using case-control and cohort studies. Int. J. Epidemiol. 13(1), 87–3.
Smith, R., Blower, S., 2004. Could disease-modifying HIV vaccines cause population-level perversity? Lancet Infect. Dis. 4(10), 636–39.
Thiebaut, R., Jacqmin-Gadda, H., Babiker, A., Commenges, D., the Cascade Collaboration, 2005. Joint modelling of bivariate longitudinal data with informative dropout and left censoring, with application to the evolution of CD4+ cell counts and HIV RNA viral load in response to treatment of HIV infection. Stat. Med. 24, 65–2.
Toth, G., 2000. Survival after introduction of HAART in people with known duration of HIV-1 infection. Lancet 355, 1158–159.
UNAIDS, 2007.2007 AIDS epidemic update. http://www.unaids.org/en/HIV_data/2007EpiUpdate/default.asp.
van den Driessche, P., Watmough, J., 2002. Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission. Math. Biosci. 180(1–2), 29–8.
Vittinghoff, E., Douglas, J., Judson, F., McKirnan, D., MacQueen, K., Buchbinder, S., 1999. Per-contact risk of human immunodeficiency virus transmission between male sexual partners. Am. J. Epidemiol. 150(3), 306–11.
Watkins, D., Burton, D., Kallas, E., Moore, J., Koff, W., 2008. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat. Med. 14(6), 617–21.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rida, W., Sandberg, S. Modeling the Population Level Effects of an HIV-1 Vaccine in an Era of Highly Active Antiretroviral Therapy. Bull. Math. Biol. 71, 648–680 (2009). https://doi.org/10.1007/s11538-008-9375-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11538-008-9375-5